Sun Pharma s partner, Philogen, has reported positive results in late-stage clinical trials for its new drug, Nidlegy, which is used to treat skin cancers. In the trial, Nidlegy demonstrated a statistically significant improvement in recurrence-free survival for patients with resectable melanoma. The study compared Nidlegy followed by surgery with surgery alone. The treatment arm showed a reduction in the hazard risk ratio, and treatment-related adverse events were reported to be benign and manageable. Nidlegy is also being developed for the treatment of other types of skin cancers.
Updated Covid-19 boosters that carry instructions to arm the body against currently circulating Omicron subvariants offer some protection against infections, according to the first study to look at how the
According to Fortune Business Insights, The Allergic Conjunctivitis Market size is anticipated to reach USD 3.60 Billion by 2028, the market size was USD.